<DOC>
	<DOCNO>NCT00002132</DOCNO>
	<brief_summary>To evaluate safety efficacy itraconazole oral solution versus fluconazole tablet treatment esophageal candidiasis immunocompromised patient .</brief_summary>
	<brief_title>Randomized , Controlled , Double-Blind Study Itraconazole Oral Solution Versus Fluconazole Tablets Treatment Esophageal Candidiasis .</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<criteria>Inclusion Criteria Patients must : Esophageal candidiasis . Histological evidence Candida spp . baseline confirmation positive mycological culture . HIV infection predispose risk factor . Life expectancy least 2 month . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Malignancies head neck , treatment disease interfere response assessment . Evidence systemic fungal infection . Underlying clinical condition would preclude study completion . Judged unreliable regard follow physician 's directive . Concurrent Medication : Excluded : Rifampin . Rifabutin . Phenobarbital . Phenytoin . Carbamazepine . Terfenadine . Astemizole . H2 blocker . Continual antacid . Any investigational drug ( expanded access drug allow ) . Patients follow prior condition exclude : History significant hepatic abnormality clinical evidence hepatic disease within 2 month prior study entry . History hypersensitivity imidazole azole compound . Prior Medication : Excluded : Other orally administer antifungal therapy within 3 day prior study entry . Any investigational drug within 1 month prior study entry ( expanded access drug allow ) .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 1996</verification_date>
	<keyword>Itraconazole</keyword>
	<keyword>Fluconazole</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Candidiasis</keyword>
	<keyword>Immunocompromised Host</keyword>
</DOC>